Skip to content

Movement Disorders Analysis Using a Deep Learning Approach

Movement Disorders Analysis Using a Deep Learning Approach

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04974034
Enrollment
50
Registered
2021-07-23
Start date
2019-06-01
Completion date
2020-12-31
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Akinesia, Bradykinesia, Hypokinesia, Parkinson Disease, Parkinsonian Disorders, Parkinsonian Syndrome

Keywords

Deep Learning, Bradykinesia, Parkinson Disease

Brief summary

Bradykinesia is a key parkinsonian feature yet subjectively assessed by the MDS-UPDRS score, making reproducible measurements and follow-up challenging. In a Movement Disorder Unit, the investigators acquired a large database of videos showing parkinsonian patients performing Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III protocols. Using a Deep Learning approach on these videos, the investigators aimed to develop a tool to compute an objective score of bradykinesia from the three upper limb tests described in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III.

Interventions

None listed

Sponsors

Hospital Avicenne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 18 years

Exclusion criteria

* Refusal of participation

Design outcomes

Primary

MeasureTime frameDescription
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score1 dayAutomatic Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III for hand bradykinesia including the three following specific tasks (finger tapping, hand movements and pronation-supination movements of hand). The minimum score is 0. The maximum score is 12 Higher scores mean wors outcome

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026